physIQ develops a cloud-based, FDA 510(k)-cleared analytics platform that processes multiple vital signs from wearable sensors to create personalized dynamic baselines for each individual. The platform maps vital-sign relationships to detect subtle deviations that can precede disease exacerbation or health changes. physIQ markets its technology to providers, health systems, payers, and pharmaceutical and medical device companies for proactive care and clinical-trial support using Real World Data. The company emphasizes scalable personalized physiology analytics to enable proactive care delivery models. physIQ is pursuing closer collaboration with Purdue’s Weldon School of Biomedical Engineering on signal processing, AI-based data analysis from wearable biosensors, and multi-axis accelerometer data. The company is led by founder Gary Conkright and is affiliated with Purdue University in West Lafayette, Indiana. Recently it received an investment to advance its AI innovations and FDA-cleared physiology analytics. PhysIQ offers the VitaLink end-to-end solution: a cloud-based software platform and AI analytics suite paired with third-party wearable biosensors, a mobile Android device for secure transmission, and a clinician user interface. The platform is FDA 510(k)-cleared, device-agnostic, engineered to be massively scalable and capable of continuously monitoring tens of thousands of patients. Its Personalized Physiology Analytics create individualized dynamic baselines and detect subtle deviations that may precede clinical deterioration across conditions such as heart failure, COPD, oncology, and chronic pain. Healthcare providers, payers, and pharmaceutical and medical device companies use the analytics for proactive ambulatory patient management and to integrate real-world data into clinical trials. PhysIQ’s technology is protected by over 100 issued patents. The company is preparing a commercial launch of VitaLink and will use the recent financing to support that rollout. PhysIQ is a Naperville, IL spinout from Argonne National Laboratory that develops proprietary personalized physiology analytics (PPA). Its PPA technology learns the unique interplay between continuous physiological signals to establish individualized baselines. Signals noted in the article include heart rate, respiration rate, oxymetry and blood pressure, among others. The system creates a dynamic multivariate baseline for each patient to track physiological patterns over time. The company has recently raised capital, indicating external investor interest in its platform. No operating metrics such as revenue or user counts were disclosed in the article.

Total raised

$13M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2020